@Phaedrus Yes the Chairman's role is about strategy and is an overarching one.
People can forget this separation from more day to day operations.
I interpret the change to be an indication that with persistence and at times frustrating setbacks, Swedish has achieved what was needed in terms of strategy.
The rest is just a matter of time and delivery because we now have certainty about the FDA's pathway (which previously has been inconsistent at best).
Not wasting any time with Ms Bell having a M&A legal background on the ASX, and I agree this is key to future proofing the company.
With serious buying from the Board or from partners in trials, I take this as one way of ensuring it gets into the right hands.
We don't know who everyone really is, out in the marketplace. It's bad enough in here.
@Phaedrus Yes the Chairman's role is about strategy and is an...
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
-0.030(2.03%) |
Mkt cap ! $1.655B | |||
| Open | High | Low | Value | Volume |
| $1.48 | $1.51 | $1.43 | $6.613M | 4.498M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2482 | $1.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.46 | 27045 | 2 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |